← Back to Screener
Aura Biosciences, Inc. Common Stock (AURA)
Price$6.88
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)11.87%
Price vs S&P 500 (4W)-27.42%
VGM Score64.02
Market Capitalization$713.37M
All Metrics
Book Value / Share (Quarterly)$1.67
P/TBV (Annual)2.02x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.43
Price vs S&P 500 (YTD)15.22%
EPS (TTM)$-1.74
10-Day Avg Trading Volume0.44M
EPS Excl Extra (TTM)$-1.74
EPS (Annual)$-1.76
ROI (Annual)-77.56%
Cash / Share (Quarterly)$1.75
ROA (Last FY)-62.68%
EBITD / Share (TTM)$-1.82
ROE (5Y Avg)-44.35%
Cash Flow / Share (Annual)$-1.34
P/B Ratio6.65x
P/B Ratio (Quarterly)4.00x
Net Income / Employee (Annual)$-939,700
Net Interest Coverage (TTM)-483.00x
ROA (TTM)-64.08%
EPS Incl Extra (Annual)$-1.76
Current Ratio (Annual)8.15x
Quick Ratio (Quarterly)6.77x
3-Month Avg Trading Volume0.40M
52-Week Price Return12.01%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$3.97
52-Week High$9.54
EPS Excl Extra (Annual)$-1.76
CapEx CAGR (5Y)-10.31%
26-Week Price Return25.45%
Quick Ratio (Annual)7.91x
13-Week Price Return12.38%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)7.09x
Enterprise Value$628.57M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$2.27
3-Month Return Std Dev64.84%
Net Income / Employee (TTM)$-994,600
ROE (Last FY)-77.56%
EPS Basic Excl Extra (Annual)$-1.76
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.74
ROI (TTM)-78.12%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$5.18
Price vs S&P 500 (52W)-16.14%
Year-to-Date Return26.61%
5-Day Price Return-9.92%
EPS Normalized (Annual)$-1.76
ROA (5Y Avg)-37.71%
Month-to-Date Return-7.63%
Cash Flow / Share (TTM)$-1.91
EBITD / Share (Annual)$-1.85
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-44.35%
EPS Basic Excl Extra (TTM)$-1.74
P/TBV (Quarterly)2.60x
P/B Ratio (Annual)2.53x
Book Value / Share (Annual)$2.15
Price vs S&P 500 (13W)1.71%
Beta0.39x
Revenue / Share (TTM)$0.00
ROE (TTM)-78.12%
52-Week Low$4.73
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.50est. -0.41
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.17
4.17
4.17
4.17
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
AURAAura Biosciences, Inc. Common Stock | — | — | B | $6.88 |
| AMGNAmgen Inc | C | C | C | $338.22 |
| GILDGilead Sciences Inc | C | B | C | $128.99 |
| ARGXargenx SE American Depositary Shares | D | A | B | $813.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $155.99 |
| BIIBBiogen Inc. Common Stock | B | D | C | $195.96 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.45 |
| MRNAModerna, Inc. Common Stock | C | B | C | $49.06 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $165.11 |
| EXELExelixis Inc | C | B | B | $51.60 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $301.82 |
About
Aura Biosciences is a clinical-stage biotechnology company developing precision immunotherapies designed to treat solid tumors while preserving organ function. Its lead candidate, bel-sar, is in late-stage clinical trials for primary choroidal melanoma and other ocular cancers, with early-stage development in bladder cancer. The company operates exclusively in the United States.